Community Corner: New FDA Approval for Briviact Use in Young Children

Epilepsy News From: Wednesday, May 16, 2018

Briviact® CV (compund name brivaracetam)

The U.S. Food and Drug Administration (FDA) has approved the use of Briviact, from UCB, in children 4 years of age or older. Previously it was approved for people age 16 and older.

  • This seizure medication is approved for use alone or with other seizure medications for the treatment of focal or partial seizures (also called focal onset seizures).
  • Briviact is available in both tablet and liquid form.
  • The form of Briviact for injections (given into a vein) is approved only for people age 16 and older.

The ability to use Briviact in young children will be of great benefit to children who continue to have seizures despite current therapies.

Learn more about Briviact

Authored by

Patty Obsorne Shafer RN, MN

Reviewed by

Joseph I. Sirven MD

Reviewed Date

Wednesday, May 16, 2018

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.